Literature DB >> 16260852

Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.

Faruk Tas1, Derya Duranyildiz, Andac Argon, Hilal Oğuz, Hakan Camlica, Vildan Yasasever, Erkan Topuz.   

Abstract

In this study, we aimed to investigate the diagnostic and prognostic roles and the effects of chemotherapy of serum proinflammatory cytokines consisting of IL-6, TNF-alpha, CRP, and leptin levels in patients with advanced-stage non-small cell lung cancer. Twenty-eight patients newly diagnosed of non-surgical advanced non-small cell lung cancer and 15 healthy controls were included. All patients with good performance status were treated with combination therapy consisting of cisplatin plus vinorelbine chemotherapy. Blood samples were obtained in fasting conditions before chemotherapy first and after two cycles of chemotherapy. IL-6 and TNF-alpha immunoassays employ the quantitative sandwich enzyme immunoassay technique. Leptin (Sandwich) ELISA is a solid-phase enzyme-linked immunosorbent assay based on the sandwich principle. CRP is a photometric immunoturbidimetric test. Most of the patients were elderly, male predominance, good performance status, and no or less than 10% weight loss. Higher serum TNF-alpha (p < 0.001) and CRP (p < 0.001), and lower leptin (p = 0.021) levels in patients than in controls. Serum IL-6 cytokine (p = 0.693) levels were not significantly different. No statistically significant relationships between investigated serum parameters and various characteristics of patient and disease. Likewise, serum levels of leptin, IL-6, TNF-alpha, and CRP were all similar in lung cancer patients independently from severity of weight loss (p > 0.05). A direct relationship was found between serum IL-6 and TNF-alpha levels (r = 0.530, p = 0.004). We found that both serum leptin (p = 0.046) and IL-6 (p = 0.002) levels were decreased owing to the chemotherapy effect independently from chemotherapy response. However, serum TNF-alpha and CRP levels were not changed by the chemotherapy effect. The stage of the disease, serum LDH levels, performance status, and responsiveness to chemotherapy yielded prognostic value. Only serum IL-6 levels out of the parameters showed a trend (p = 0.06) related to a worse prognosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16260852     DOI: 10.1385/MO:22:4:353

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  24 in total

Review 1.  Proinflammatory cytokines.

Authors:  C A Dinarello
Journal:  Chest       Date:  2000-08       Impact factor: 9.410

2.  [Prognostic value of the nutrition status and pro-inflammatory cytokines (IL-1, TNF-alpha and IL-6) in critically ill patients].

Authors:  A Tormo Cantos; F Santolaria Fernández; A Milena Abril; E González Reimers; M Rodríguez Gaspar; F Rodríguez Moreno; A Martínez Riera; M R Alemán Valls
Journal:  An Med Interna       Date:  1999-11

Review 3.  The host-tumor immune conflict: from immunosuppression to resistance and destruction.

Authors:  S Chouaib; C Asselin-Paturel; F Mami-Chouaib; A Caignard; J Y Blay
Journal:  Immunol Today       Date:  1997-10

4.  Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites.

Authors:  G Mantovani; A Macciò; C Madeddu; L Mura; E Massa; M C Mudu; C Mulas; M R Lusso; G Gramignano; M B Piras
Journal:  J Mol Med (Berl)       Date:  2001-07       Impact factor: 4.599

5.  [The value of serum C-reactive protein as a survival determinant in patients with advanced non-small-cell lung cancer].

Authors:  K Kato; Y Hitsuda; Y Kawasaki; T Igishi; K Yasuda; M Mikami; M Watanabe; M Miyata; T Sasaki; E Shimizu
Journal:  Nihon Kokyuki Gakkai Zasshi       Date:  2000-08

Review 6.  Leptin leads hypothalamic feeding circuits in a new direction.

Authors:  Joanne A Harrold
Journal:  Bioessays       Date:  2004-10       Impact factor: 4.345

7.  Both TNF receptors are required for direct TNF-mediated cytotoxicity in microvascular endothelial cells.

Authors:  R Lucas; I Garcia; Y R Donati; M Hribar; S J Mandriota; C Giroud; W A Buurman; L Fransen; P M Suter; G Nunez; M S Pepper; G E Grau
Journal:  Eur J Immunol       Date:  1998-11       Impact factor: 5.532

8.  Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis.

Authors:  M G Alexandrakis; F H Passam; K Perisinakis; E Ganotakis; G Margantinis; D S Kyriakou; D Bouros
Journal:  Respir Med       Date:  2002-08       Impact factor: 3.415

9.  Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.

Authors:  Masami Niiya; Kenji Niiya; Toru Kiguchi; Misako Shibakura; Noboru Asaumi; Katsuji Shinagawa; Fumihiko Ishimaru; Katsuyuki Kiura; Kazuma Ikeda; Hiroshi Ueoka; Mitsune Tanimoto
Journal:  Cancer Chemother Pharmacol       Date:  2003-08-08       Impact factor: 3.333

10.  Prognostic value of serial serum interleukin-6 level estimation in patients with lung cancer: a preliminary report.

Authors:  A Wojciechowska-Lacka; E Adamiak; G Stryczynska; J K Lacki
Journal:  Yale J Biol Med       Date:  1997 Mar-Apr
View more
  30 in total

1.  Clinical significance of serum adipokines levels in lung cancer.

Authors:  Theodora Kerenidi; Martha Lada; Agori Tsaroucha; Panagiotis Georgoulias; Parthena Mystridou; Konstantinos I Gourgoulianis
Journal:  Med Oncol       Date:  2013-02-22       Impact factor: 3.064

2.  Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma.

Authors:  Gaspar Reynés; Virtudes Vila; María Martín; Antonio Parada; Tania Fleitas; Edelmiro Reganon; Vicenta Martínez-Sales
Journal:  J Neurooncol       Date:  2010-07-06       Impact factor: 4.130

3.  Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians.

Authors:  Lindsey Enewold; Leah E Mechanic; Elise D Bowman; Yun-Ling Zheng; Zhipeng Yu; Glenwood Trivers; Anthony J Alberg; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

4.  Cytokine and cytokine receptor single-nucleotide polymorphisms predict risk for non-small cell lung cancer among women.

Authors:  Alison L Van Dyke; Michele L Cote; Angie S Wenzlaff; Wei Chen; Judith Abrams; Susan Land; Craig N Giroux; Ann G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-06       Impact factor: 4.254

Review 5.  Immune-pineal axis - acute inflammatory responses coordinate melatonin synthesis by pinealocytes and phagocytes.

Authors:  Regina P Markus; Pedro A Fernandes; Gabriela S Kinker; Sanseray da Silveira Cruz-Machado; Marina Marçola
Journal:  Br J Pharmacol       Date:  2017-12-15       Impact factor: 8.739

6.  Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers.

Authors:  Anne E Utech; Eiriny M Tadros; Teresa G Hayes; Jose M Garcia
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-05-31       Impact factor: 12.910

Review 7.  The role of leptin in the respiratory system: an overview.

Authors:  Foteini Malli; Andriana I Papaioannou; Konstantinos I Gourgoulianis; Zoe Daniil
Journal:  Respir Res       Date:  2010-10-31

8.  Pathophysiology and treatment of inflammatory anorexia in chronic disease.

Authors:  Theodore P Braun; Daniel L Marks
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

Review 9.  A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Authors:  Katriina Heikkilä; Shah Ebrahim; Debbie A Lawlor
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

10.  Changes in plasma ghrelin and serum leptin levels after Cisplatin-based transcatheter arterial infusion chemotherapy for hepatocellular carcinoma.

Authors:  Tomoaki Matsumura; Makoto Arai; Masaharu Yoshikawa; Kentaro Sudo; Kazuyoshi Nakamura; Tatsuro Katsuno; Fumihiko Kanai; Taketo Yamaguchi; Osamu Yokosuka
Journal:  ISRN Gastroenterol       Date:  2013-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.